Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The effect of Ranibizumab (Lucentis) combined with grid laser compared with laser alone on vision in patients with recalcitrant, diabetic macular oedema

Trial Profile

The effect of Ranibizumab (Lucentis) combined with grid laser compared with laser alone on vision in patients with recalcitrant, diabetic macular oedema

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms DMO Rescue Trial
  • Sponsors Novartis

Most Recent Events

  • 08 Jun 2016 Status changed from recruiting to completed.
  • 24 Jan 2011 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top